Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety and PK of ABX-002 in Healthy Adults
NCT05528315Phase 1Completed
- Sponsor
- Autobahn Therapeutics
- Start
- Oct 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of elunetirom in major depressive disorder (MDD) (3 arms), sponsored by Autobahn Therapeutics. Primary endpoint: Incidence of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs). Started Oct 2022; status: completed.
02
Drugs
elunetirom
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05528315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05528315.